PL236355B1 - Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 - Google Patents

Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 Download PDF

Info

Publication number
PL236355B1
PL236355B1 PL411864A PL41186415A PL236355B1 PL 236355 B1 PL236355 B1 PL 236355B1 PL 411864 A PL411864 A PL 411864A PL 41186415 A PL41186415 A PL 41186415A PL 236355 B1 PL236355 B1 PL 236355B1
Authority
PL
Poland
Prior art keywords
alkyl
compound
formula
group
methyl
Prior art date
Application number
PL411864A
Other languages
English (en)
Polish (pl)
Other versions
PL411864A1 (pl
Inventor
Barbara DYMEK
Barbara Dymek
Marcin ZAGOZDA
Marcin Zagozda
Maciej Wieczorek
Krzysztof DUBIEL
Krzysztof Dubiel
Aleksandra STAŃCZAK
Aleksandra Stańczak
Daria Zdżalik
Paweł Gunerka
Mariola SEKULAR
Mariola Sekular
Maciej DZIACHAN
Maciej Dziachan
Original Assignee
Celon Pharma Spolka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spolka Akcyjna filed Critical Celon Pharma Spolka Akcyjna
Priority to PL411864A priority Critical patent/PL236355B1/pl
Priority to CA2978828A priority patent/CA2978828A1/en
Priority to CN201680017259.4A priority patent/CN107743489B/zh
Priority to EA201792087A priority patent/EA032826B1/ru
Priority to AU2016241568A priority patent/AU2016241568B2/en
Priority to PCT/IB2016/051792 priority patent/WO2016157091A1/en
Priority to SI201630560T priority patent/SI3277687T1/sl
Priority to ES16714019T priority patent/ES2765642T3/es
Priority to JP2017551627A priority patent/JP6665201B2/ja
Priority to BR112017020131-3A priority patent/BR112017020131B1/pt
Priority to HUE16714019A priority patent/HUE047822T2/hu
Priority to KR1020177031214A priority patent/KR102559190B1/ko
Priority to MX2017011423A priority patent/MX2017011423A/es
Priority to EP16714019.3A priority patent/EP3277687B1/en
Priority to PT167140193T priority patent/PT3277687T/pt
Priority to HRP20192195TT priority patent/HRP20192195T1/hr
Priority to PL16714019T priority patent/PL3277687T3/pl
Priority to DK16714019.3T priority patent/DK3277687T3/da
Priority to US15/562,537 priority patent/US10138247B2/en
Publication of PL411864A1 publication Critical patent/PL411864A1/pl
Publication of PL236355B1 publication Critical patent/PL236355B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL411864A 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 PL236355B1 (pl)

Priority Applications (19)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CA2978828A CA2978828A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
CN201680017259.4A CN107743489B (zh) 2015-04-02 2016-03-30 治疗免疫疾病、炎性疾病或癌症的7-(吗啉-4-基)吡唑并[1，5-a]嘧啶衍生物
EA201792087A EA032826B1 (ru) 2015-04-02 2016-03-30 ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
AU2016241568A AU2016241568B2 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
SI201630560T SI3277687T1 (sl) 2015-04-02 2016-03-30 7-(morfolin-4-IL)pirazol(1,5-A)pirimidinski derivati, ki so uporabni za zdravljenje imunskih ali vnetnih bolezni ali raka
ES16714019T ES2765642T3 (es) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazol[1,5-a]pirimidina que son útiles para el tratamiento de enfermedades inmunitarias o inflamatorias o cáncer
JP2017551627A JP6665201B2 (ja) 2015-04-02 2016-03-30 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体
BR112017020131-3A BR112017020131B1 (pt) 2015-04-02 2016-03-30 Composto, seu uso e composição farmacêutica
HUE16714019A HUE047822T2 (hu) 2015-04-02 2016-03-30 Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok
KR1020177031214A KR102559190B1 (ko) 2015-04-02 2016-03-30 면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체
MX2017011423A MX2017011423A (es) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.
EP16714019.3A EP3277687B1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
PT167140193T PT3277687T (pt) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazole[1,5-a]pirimidina que são úteis para o tratamento de doenças imunitárias ou inflamatórias ou cancro
HRP20192195TT HRP20192195T1 (hr) 2015-04-02 2016-03-30 Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów
DK16714019.3T DK3277687T3 (da) 2015-04-02 2016-03-30 7-(Morpholin-4-yl)pyrazol[1,5-a]pyrimidinderivater, som kan anvendes til behandling af immunsygdomme eller inflammatoriske sygdomme eller cancer
US15/562,537 US10138247B2 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-A]pyrimidine derivatives as PI3 kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3

Publications (2)

Publication Number Publication Date
PL411864A1 PL411864A1 (pl) 2016-10-10
PL236355B1 true PL236355B1 (pl) 2021-01-11

Family

ID=55650626

Family Applications (2)

Application Number Title Priority Date Filing Date
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów

Country Status (18)

Country Link
US (1) US10138247B2 (https=)
EP (1) EP3277687B1 (https=)
JP (1) JP6665201B2 (https=)
KR (1) KR102559190B1 (https=)
CN (1) CN107743489B (https=)
AU (1) AU2016241568B2 (https=)
BR (1) BR112017020131B1 (https=)
CA (1) CA2978828A1 (https=)
DK (1) DK3277687T3 (https=)
EA (1) EA032826B1 (https=)
ES (1) ES2765642T3 (https=)
HR (1) HRP20192195T1 (https=)
HU (1) HUE047822T2 (https=)
MX (1) MX2017011423A (https=)
PL (2) PL236355B1 (https=)
PT (1) PT3277687T (https=)
SI (1) SI3277687T1 (https=)
WO (1) WO2016157091A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
WO2022064459A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
US20240018151A1 (en) * 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
BRPI0607927A2 (pt) * 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
HRP20100516T1 (hr) * 2006-09-20 2010-10-31 Eli Lilly And Company Tiazolpirazolopirimidini kao antagonisti receptora crf1
US20110230464A1 (en) 2007-10-26 2011-09-22 Paul Goldsmith Purine derivatives useful as p13 kinase inhibitors
MX2010009416A (es) 2008-02-26 2010-09-24 Novartis Ag Compuestos heterociclicos como inhibidores de cxcr2.
CA2721851A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
JP5578490B2 (ja) * 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
US8969364B2 (en) 2010-03-04 2015-03-03 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
BR112017020131A2 (pt) 2018-05-29
KR102559190B1 (ko) 2023-07-25
JP2018510192A (ja) 2018-04-12
ES2765642T3 (es) 2020-06-10
HUE047822T2 (hu) 2020-05-28
EP3277687B1 (en) 2019-10-30
CN107743489B (zh) 2021-05-04
EA032826B1 (ru) 2019-07-31
DK3277687T3 (da) 2019-12-16
PL411864A1 (pl) 2016-10-10
CN107743489A (zh) 2018-02-27
EP3277687A1 (en) 2018-02-07
EA201792087A1 (ru) 2018-03-30
JP6665201B2 (ja) 2020-03-13
MX2017011423A (es) 2018-05-17
SI3277687T1 (sl) 2020-02-28
PL3277687T3 (pl) 2020-09-21
HRP20192195T1 (hr) 2020-03-06
PT3277687T (pt) 2020-01-10
US20180111939A1 (en) 2018-04-26
BR112017020131B1 (pt) 2023-02-28
KR20170132275A (ko) 2017-12-01
CA2978828A1 (en) 2016-10-06
US10138247B2 (en) 2018-11-27
AU2016241568B2 (en) 2019-09-26
AU2016241568A1 (en) 2017-10-19
WO2016157091A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
AU767558B2 (en) Aromatic nitrogenous six-membered ring compounds
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
KR102732646B1 (ko) 페닐 트리아졸 mll1-wdr5 단백질-단백질 상호 작용 억제제
WO2009122180A1 (en) Pyrimidine derivatives capable of inhibiting one or more kinases
US11858897B2 (en) Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
EP4536662A1 (en) Indazole macrocycles for the treatment of autoimmune disease
TWI472530B (zh) 蛋白質激酶抑制劑
WO2020092638A1 (en) Heterocyclic compounds as bet inhibitors
PL236355B1 (pl) Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
JP2010526866A (ja) 神経変性疾患の治療のためのアリールアミドピリミドン誘導体
EP3847170B1 (en) Novel cyclic amidine compounds for the treatment of autoimmune disease
CN105916506A (zh) 作为tam家族激酶抑制剂的喹唑啉衍生物
CN109641909B (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN114761406A (zh) 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
EP4182322B1 (en) Pyrido oxazine derivatives as alk5 inhibitors
KR20210149077A (ko) 포스포이노시타이드 3-키나아제 억제제로서 아이소크로멘 유도체
KR20110098852A (ko) 3-(3-피리미딘-2-일-벤질)-［1,2,4］트리아졸로［4,3-ｂ］피리다진 유도체
CN120607491A (zh) 2,4-二氨基嘧啶类化合物及其用途
HK40071777A (en) HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
JP2023503875A (ja) 新規なトリアゾロピリジン誘導体およびこれを含む薬学組成物